预约演示
更新于：2025-10-23
Dulaglutide
度拉糖肽
更新于：2025-10-23
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2014-09-18), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 51033
来源: *****
关联
131
项与 度拉糖肽 相关的临床试验NCT06851962
Single-blinded, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With Insufficiently Controlled Type 2 Diabetes
NCT06739122
A Phase 3, Open-Label, Multicenter, Single-Arm Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Dulaglutide 3.0 mg and 4.5 mg in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus
NCT06779929
Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT)
100 项与 度拉糖肽 相关的临床结果
登录后查看更多信息
100 项与 度拉糖肽 相关的转化医学
登录后查看更多信息
100 项与 度拉糖肽 相关的专利（医药）
登录后查看更多信息
1,297
项与 度拉糖肽 相关的文献（医药）2025-12-01INTERNATIONAL JOURNAL OF CARDIOLOGY
Effects of oral semaglutide on cardiovascular outcomes: A systematic review and meta-analysis
Review
作者: Ribeiro, Danilo Monteiro ; Said, Thomas Benevides ; de Araujo Paysano, Maria Lúcia Brito ; Matheus, Gustavo Tadeu Freitas Uchôa ; Kelly, Francinny Alves ; Rebelo, Thiago Gorayeb
BACKGROUND:
Cardiovascular disease remains a leading cause of morbidity and mortality in type 2 diabetic mellitus (T2DM) patients. While injectable GLP-1 RAs have demonstrated efficacy in reducing cardiovascular risk, an oral formulation of semaglutide was developed to improve accessibility and treatment adherence, however, its therapeutic potential has yet to be fully elucidated. This meta-analysis evaluates the efficacy of oral semaglutide on cardiovascular outcomes to better inform clinical decision-making.
METHODS:
A systematic search was conducted in major databases for randomized controlled trials (RCTs) up to May 2025, with a primary outcome of cardiovascular events, expanded outcomes included nonfatal stroke, death from cardiovascular cause, and nonfatal myocardial infarction, and the secondary outcome was all-cause mortality. Statistical analysis was performed using RStudio, with heterogeneity assessed via I2 statistics.
RESULTS:
A total of 13,875 patients were included, of whom 6935 received oral semaglutide and 6940 received placebo from the 5 eligible studies. A significant difference was observed for cardiovascular events with a risk ratio (RR) of 0.86 (95 % CI: 0.78-0.95; p = 0.0029; I2 = 0 %) and hazard ratio (HR) of 0.85 (95 % CI: 0.77-0.95), respectively. In contrast, no significant difference was found for nonfatal stroke, all-cause mortality, death from cardiovascular causes, and nonfatal myocardial infarction.
CONCLUSION:
The meta-analysis revealed that oral semaglutide was cardioprotective in T2DM patients with consistent reductions in cardiovascular event risk. However, the lack of significance in the remaining outcomes underscores the need for further investigation.
2025-12-01Journal of Orthopaedics
Glucagon-like Peptide-1 receptor agonist use is not associated with increased reoperation risk following rotator cuff repair
Article
作者: Ilyas, Asif M ; Rasmussen, Spencer T
Objectives:
The use of glucagon-like peptide-1 (GLP-1) receptor agonists is increasingly common among orthopaedic patients, often prescribed for type 2 diabetes mellitus and obesity, which are frequent comorbidities. Recent studies have explored the effects of GLP-1's on postoperative outcomes in orthopaedic procedures. This study evaluates the impact of GLP-1 on re-operation risk following rotator cuff repair (RCR).
Methods:
A retrospective cohort analysis of patients aged 18 and older from 2014 to 2024 was conducted using the TriNetX US collaborative network. Patients with documented RCR and no prior GLP-1 use were included in the control group. Those taking semaglutide, dulaglutide, or liraglutide for at least 3 months before RCR comprised the GLP-1 group. After comparing baseline characteristics, cohorts were matched based on selected covariates. Outcomes were compared using risk ratios (RR) with 95 % confidence intervals (CI). A subgroup analysis by GLP-1 indication (type 2 diabetes or weight loss) was performed.
Results:
Propensity score matching yielded well-balanced cohorts of 5306 patients. Subgroup analysis included 781 patients per group. At 3, 6, and 12 months post-RCR, the control group showed no difference in reoperation risk. In a sub-analysis of the GLP-1 group, those receiving it for diabetes, compared to obesity, showed an increased risk of adhesive capsulitis at 3 months (RR = 2.20, 95 % CI [1.05-4.62], P = 0.0321).
Conclusion:
The use of GLP-1 was not associated with a higher reoperation risk after RCR, suggesting that these medications can safely be taken leading up to RCR. However, increased short-term risks in diabetes patients highlight the need for individualized care and further study of GLP-1 effects on orthopaedic outcomes.
2025-12-01Journal of Gynecology Obstetrics and Human Reproduction
Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis
Review
作者: Armstrong, Bruna Benigna Sales ; Martin, Giovanna Cristina de Castro ; Amador, Wellgner Fernandes Oliveira ; Machado, Guilherme Franceschini ; Servidoni, Ana Clara Pimenta ; Yousif, Abdelrahman
OBJECTIVE:
Primary endpoint is maternal and fetal complications during pregnancy, labor, and delivery after exposure to GLP-1 receptor agonists.
DATA SOURCES:
A systematic search was conducted across PubMed, Embase, and Cochrane Central databases, including studies published from 2020 to 2025.
STUDY ELIGIBILITY CRITERIA:
Included studies: (1) RCTs or cohorts; (2) exposure to GLP-1 RAs during pregnancy or preconception; (3) control group not exposed to GLP-1 RAs. Excluded studies: (1) without outcomes of interest; (2) lacking data transparency; (3) retracted; (4) abstracts, case reports, reviews; (5) no control group.
STUDY APPRAISAL AND SYNTHESIS METHODS:
Six studies evaluated GLP-1 RA exposure during preconception or first trimester. Two authors screened studies; a third resolved disagreements. Risk of bias was assessed with ROBINS-I and RoB 2. Meta-analysis pooled continuous outcomes with mean differences and binary outcomes with odds ratios. Heterogeneity was evaluated via Cochrane Q and I². Subgroup analysis focused on first-trimester exposure.
RESULTS:
No statistically significant differences in pregnancy outcomes between GLP-1 RA and control group, including fetal growth restriction or small for gestational age (p = 0.12), live births (p = 0.10), major birth defects (p = 0.79), miscarriages (p = 0.41), preterm delivery (p = 0.62); and stillbirths (p = 0.09). GLP-1 RAs were linked to a lower risk of congenital heart defects (p = 0.03), even in the subgroup analysis (p = 0.03), and showed no significant protective effect against gestational diabetes (p = 0.49). In subgroup analysis, there were no notable differences in miscarriage (p = 0.32), major birth defects (p = 0.83) and preterm delivery (p = 0.88); there were fewer live births that did not reach statistical significance (p = 0.06).
CONCLUSION:
No statistically significant difference was observed between the control and intervention groups. GLP-1 RAs were connected to a lower risk of congenital heart defects.
100 项与 度拉糖肽 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2014-09-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 低血糖 | 临床3期 | 日本 | 2021-04-13 | |
| 慢性肾病 | 临床3期 | 美国 | 2012-07-01 | |
| 慢性肾病 | 临床3期 | 巴西 | 2012-07-01 | |
| 慢性肾病 | 临床3期 | 匈牙利 | 2012-07-01 | |
| 慢性肾病 | 临床3期 | 墨西哥 | 2012-07-01 | |
| 慢性肾病 | 临床3期 | 波兰 | 2012-07-01 | |
| 慢性肾病 | 临床3期 | 罗马尼亚 | 2012-07-01 | |
| 慢性肾病 | 临床3期 | 南非 | 2012-07-01 | |
| 慢性肾病 | 临床3期 | 西班牙 | 2012-07-01 | |
| 慢性肾病 | 临床3期 | 乌克兰 | 2012-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 255 | 鬱夢夢壓範膚鬱簾鑰襯(淵夢鬱窪鏇選鬱齋膚膚) = systolic blood pressure was stable over the period of 52 weeks after smoking cessation 觸網鹽網襯簾構鏇範遞 (鑰鏇獵衊顧襯獵鬱夢衊 ) | - | 2025-10-10 | |||
临床3期 | 621 | ecnoglutide 0.6 mg | 選餘壓壓蓋壓鬱範壓醖(製鹽繭鑰衊選艱淵鹹鑰) = 願積網窪積蓋鬱蓋淵鹽 鏇淵鏇範積醖壓製構襯 (廠觸艱遞齋窪範鑰淵憲 ) 更多 | 积极 | 2025-08-22 | ||
ecnoglutide 1.2 mg | 選餘壓壓蓋壓鬱範壓醖(製鹽繭鑰衊選艱淵鹹鑰) = 糧築簾鬱製鏇積觸鹹憲 鏇淵鏇範積醖壓製構襯 (廠觸艱遞齋窪範鑰淵憲 ) 更多 | ||||||
临床3期 | 13,299 | 壓構鑰構選鹹積鏇艱艱(淵鏇選觸憲襯艱窪構蓋): HR = 0.92 (95.3% CI, 0.83 ~ 1.01) 达到 更多 | 非劣 | 2025-07-31 | |||
临床3期 | 15,775 | (overall cohort) | 鏇醖憲夢夢廠廠衊壓壓(夢範願觸醖築網膚觸膚) = 鑰蓋憲憲簾選餘壓齋餘 遞鹹獵鏇糧觸築蓋鹹壓 (選衊壓鹹獵選製齋窪壓 ) | 积极 | 2025-06-20 | ||
(overall cohort) | 鏇醖憲夢夢廠廠衊壓壓(夢範願觸醖築網膚觸膚) = 憲獵壓願鏇廠齋蓋觸範 遞鹹獵鏇糧觸築蓋鹹壓 (選衊壓鹹獵選製齋窪壓 ) | ||||||
N/A | 173 | 鹹積鹽艱簾鹽鏇襯蓋選(鬱簾遞積鑰艱繭簾窪窪) = Individual GLP-1RA were associated with an increased risk of GI adverse events compared with SGLT-2i. 積壓窪鑰襯簾簾繭鏇鹹 (鹽鹹觸願製繭構構蓋構 ) 更多 | 积极 | 2025-06-20 | |||
临床4期 | 212 | 廠繭選廠夢壓廠製願糧 = 遞壓衊鑰鹹艱襯衊積觸 鏇積鹽獵壓齋醖簾獵鏇 (蓋膚蓋製蓋鬱構醖餘鏇, 醖鬱積廠鹽獵築獵築艱 ~ 鏇鹹壓壓壓窪窪夢齋鬱) 更多 | - | 2025-02-05 | |||
N/A | 30 | 網艱築鑰淵廠淵鬱顧鏇(窪鏇鹹顧鹽構壓餘鑰鏇) = 構鑰顧鹹獵築廠簾鑰願 膚餘艱願夢淵鹽網衊繭 (餘繭築簾憲獵醖網艱壓 ) | 积极 | 2025-01-23 | |||
N/A | 1,099 | Durvalumab plus chemotherapy | 糧構網鹹窪網觸廠範觸(範願齋淵餘餘壓窪餘鑰) = 鏇鏇醖觸網網觸範構醖 築積鬱獵選築餘鏇壓築 (鏇鹹齋鬱齋製鏇鹹獵顧 ) | 积极 | 2025-01-23 | ||
Chemotherapy only | 糧構網鹹窪網觸廠範觸(範願齋淵餘餘壓窪餘鑰) = 遞選醖淵衊鬱構構遞窪 築積鬱獵選築餘鏇壓築 (鏇鹹齋鬱齋製鏇鹹獵顧 ) | ||||||
N/A | 晚期胆道癌 一线 | - | 襯夢窪糧齋餘艱築鬱壓(鏇選鹽窪願獵製鬱願艱) = All patients experienced adverse events (AEs), addition of lenvatinib does not increase the risk of AEs 觸願選夢淵積壓齋蓋廠 (顧選膚鹹繭築壓繭齋窪 ) | 积极 | 2025-01-23 | ||
Durvalumab + Gemcitabine-based chemotherapy | |||||||
N/A | 50 | 餘願廠鹹糧壓鏇淵齋膚(醖衊蓋衊艱製鬱獵鏇構) = Most AEs were related to chemotherapy, there were 10% immune related AEs 簾顧夢鹹鏇網廠壓膚蓋 (獵鏇廠鏇齋遞簾遞鏇築 ) | 积极 | 2025-01-23 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用